Evidence map›Paper›PMID 38186950›Full record

ArticleBiomedical engineering letters2024

MS-CFNet: a multi-scale clinical studying-based and feature extraction-guided network for breast fibroadenoma segmentation in ultrasonography.

Yongxin Guo, Yufeng Zhou

Abstract read
In one paragraph

Article in Biomedical engineering letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yongxin GuoState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016 China.
Yufeng ZhouState Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, 400016 China.ORCID 0000-0003-4086-2150

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Segmenting breast tumors in ultrasonography is challenging due to the low image quality and presence of artifacts. Radiologists' studying and diagnosis skills are integrated with artificial intelligence to establish a clinical learning-based deep learning network in order to robustly extract and delineate features of breast fibroadenoma. The spatial local feature contrast (SLFC) module captures overall tumor contours, while the channel recursive gated attention (CRGA) module enhances edge perception through high-dimensional information interaction. Additionally, full-scale feature fusion and enhanced deep supervision are applied to improve model stability and performance. To achieve smoother boundaries, we introduce a new loss function (cosh-smooth) that penalizes and finely tunes tumor edges. Our dataset comprises 1016 clinical ultrasound images of breast fibroadenoma with labeled masks, alongside a publicly available dataset of 246 ones. Segmentation performance is evaluated using the Dice similarity coefficient (DSC) and mean intersection over union (MIOU). Extensive experiments demonstrate that our proposed MS-CFNet outperforms state-of-the-art methods. Compared to TransUNet as a baseline model, MS-CFNet improves by 1.47% in DSC and 2.56% in MIOU. The promising result of MS-CFNet is attributed to the integration of radiologists' clinical diagnosis procedure and the bionic mindset, enhancing the network's ability to recognize and segment breast fibroadenomas effectively.

Indexed as

Breast fibroadenomasMulti-scale clinical studying-based networkMulti-scale feature extraction-guided networkSegmentationSonography

Identifiers

PMID38186950
PMCPMC10769961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.